Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

Ratios

vs
industry
vs
history
PE Ratio 24.23
FBT's PE Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FBT: 24.23 )
Ranked among companies with meaningful PE Ratio only.
FBT' s PE Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 24.32
Current: 24.23
0
24.32
PE Ratio without NRI 24.23
FBT's PE Ratio without NRI is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FBT: 24.23 )
Ranked among companies with meaningful PE Ratio without NRI only.
FBT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0  Med: 0 Max: 24.32
Current: 24.23
0
24.32
PB Ratio 5.04
FBT's PB Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FBT: 5.04 )
Ranked among companies with meaningful PB Ratio only.
FBT' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 5.06
Current: 5.04
0
5.06

Buy Back

vs
industry
vs
history

More Statistics

Short Percentage of Float0.00%
52-Week Range $83.69 - 118.68
Shares Outstanding (Mil)9,150,002.00
» More Articles for FBT

Headlines

Articles On GuruFocus.com
Willis Lease Announces Offering of $335.7 Million in Fixed Rate Notes Jul 18 2017 
McCormick To Acquire Reckitt Benckiser's Food Division Jul 18 2017 
CME Group Announces First Cleared Korean Won and Indian Rupee Interest Rate Swaps Trades, Amid Risin Jul 18 2017 
Tahoe Announces Amended Credit Facility Jul 18 2017 
Weyerhaeuser issues statement regarding TJI® Joists with Flak Jacket® Protection Jul 18 2017 
Aeromexico Reports 2Q17 Results Jul 18 2017 
Western Gas Announces Second Quarter 2017 Distribution And Schedules Earnings Conference Call Jul 18 2017 
Jones Energy, Inc. Announces Top-Decile Meramec Well Results, Second Quarter Production and Schedule Jul 18 2017 
Hotchkis & Wiley Large Cap Diversified Value 2nd Quarter Commentary Jul 18 2017 
Bachoco's Recent Acquisitions Disclosure Jul 18 2017 

More From Other Websites
The Rise of Amgen Stock in 2Q17 Jul 10 2017
What Analysts Recommend for United Therapeutics in June 2017 Jul 04 2017
Neurocrine Biosciences: Ingrezza, Collaborations, Ratings Jul 03 2017
The Zacks Analyst Blog Highlights: SPDR Technology ETF, SPDR S&P Biotech ETF, First Trust NYSE Arca... Jun 30 2017
Forget Big Tech, Biotech ETFs are Soaring Higher Jun 29 2017
Biotech Stocks Are Soaring, Todd Hagopian Leads The Way Jun 28 2017
ETF Flopper: Biotech Stumbles on Health Care Vote Delay Jun 27 2017
Top Biotech ETFs to Buy Jun 22 2017
Why Biotech Stocks Are Hitting the Skids May 15 2017
Ionis Pharmaceuticals’ Valuation Compared to Its Peers Mar 21 2017
Time to Buy Biotech ETF? Mar 13 2017
Alnylam Pharmaceuticals’s Therapies to Treat hATTR Amyloidosis Feb 28 2017
Biotech ETFs Powered by Q4 Earnings Feb 10 2017
Politics Plague Biotech ETFs Feb 01 2017
What Lies Ahead for Biotech ETFs in Trump Era? Jan 27 2017
Here's How to Play the Biotech Rebound Jan 25 2017
Fidelity Biotech Fund: Better than the Index? Jan 16 2017
Here's Why Merrimack Pharmaceuticals Inc. Fell 47.3% in 2016 Jan 10 2017
United Therapeutics: Will RemoSynch Become a Key Growth Driver? Dec 29 2016
How Could Gilead Sciences Restore Its Growth? Dec 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK